News Archive

Walbrook PR appointed by Shield Therapeutics Plc

01 January 2019

Walbrook PR, which provides high quality Financial PR and Investor Relations to Small Cap and AIM listed companies, announces its appointment as Financial PR & Investor Relations advisor to AIM listed Shield Therapeutics Plc (“Shield”), a de-risked commercial stage pharmaceutical company with a focus on addressing iron deficiency via its lead product Feraccru®. The team at Walbrook will manage the Company’s communications with the financial media, research analysts and non-institutional investors, including new and existing private investors.

Shield’s lead product Feraccru®, is a novel oral treatment available via prescription for the treatment of Iron Deficiency with or without anaemia which has received marketing authorisation in the European Union, where it has a commercial agreement signed with Norgine B.V., and Switzerland. An NDA (New Drug Application) was submitted to the FDA (US Food and Drug Administration) in September 2018 and has a PDUFA (Prescription Drug User Free Act) date of 27 July 2019.

The WHO state that Iron Deficiency is the most common and widespread nutritional disorder in the world. Shield’s other pipeline products include PT20, a novel iron-based phosphate binder for the treatment of hyperphosphatemia and PT40, to be the first generic version of iron sucrose.

For more information visit the Company’s website:


For further information please contact:

Paul McManus

Tel: 020 7933 8787

Mob: 07980 541 893

[email protected]



About Walbrook PR:

Walbrook PR was founded in April 2009 by Paul McManus and focuses on providing high quality Financial PR and Investor Relations to Small Cap and AIM listed companies.

Walbrook PR is ranked 2nd in the AIM Adviser Rankings guide and is ranked 7th by total number of Stock Market listed clients. Walbrook acts for 56 listed companies (mainly AIM) across a wide mix of sectors and is ranked 1st in Healthcare and 4th in Technology, by number of AIM clients.

Walbrook PR prides itself on having a strong reputation for working with growing UK Small Cap and AIM listed companies; a proven IR offering, which focuses on the Private Client Investment Management community and the retail investment community; and on having a proactive, hands-on approach from a committed team with full ownership of the business.


Who We Work With